4CPS-146 Ustekinumab and adalimumab for psoriasis patients who are no-responders to etanercept: a comparative effectiveness study

BACKGROUND: Adalimumab and ustekinumab have demonstrated high effectiveness in the treatment of moderate-severe psoriasis in randomised controlled trials. There is, however, limited data available on the comparative effectiveness of ustekinumab and adalimumab in psoriasis patients unsuccessfully tre...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Hosp Pharm
Asıl Yazarlar: Gil, S García, Nicolás, F Gutiérrez, Casariego, GJ Nazco, Bustinduy, M García, Martín-Neda, FJ Guimerá, Ramos, J Rodríguez, García, B del Rosario, García, J González
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Group 2018
Konular:
Section 4: Clinical pharmacy services
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535744/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.237
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller